Capreomycin is active against non-replicating M. tuberculosis

Annals of Clinical Microbiology and Antimicrobials

Volumn 4, Issue , 2005, Pages

  Heifets, Leonid ^a   Simon, Julie ^b   Pham, Van ^a  

^a NATIONAL JEWISH MEDICAL AND RESEARCH CENTER   (United States)

^b NONE   (United States)

Author keywords

Capreomycin; Dormant tubercle bacilli; Latent tuberculosis infection

Indexed keywords

AMIKACIN; AMOXICILLIN; AMOXICILLIN PLUS CLAVULANIC ACID; ANTIINFECTIVE AGENT; CAPREOMYCIN; CEFOXITIN; CEFTRIAXONE; CIPROFLOXACIN; CLARITHROMYCIN; CLINDAMYCIN; DAPSONE; DOXYCYCLINE; ERYTHROMYCIN; ETHAMBUTOL; ETHIONAMIDE; GATIFLOXACIN; ISONIAZID; LEVOFLOXACIN; METRONIDAZOLE; MORINAMIDE; POLYPEPTIDE ANTIBIOTIC AGENT; PYRAZINAMIDE; RIFABUTIN; RIFAMPICIN; RIFAPENTINE; SPARFLOXACIN; STREPTOMYCIN; THIOACETAZONE; TUBERCULOSTATIC AGENT; UNINDEXED DRUG;

ANTIBACTERIAL ACTIVITY; ARTICLE; BACTERIAL COUNT; BACTERIAL STRAIN; BACTERICIDAL ACTIVITY; BACTERIUM CULTURE; COLONY FORMING UNIT; CONTROLLED STUDY; IN VITRO STUDY; MOLECULAR MODEL; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; PLATING MEDIUM; SAMPLING; ANAEROBIC GROWTH; CULTURE MEDIUM; DRUG EFFECT; MICROBIAL SENSITIVITY TEST;

ANAEROBIOSIS; ANTIBIOTICS, ANTITUBERCULAR; CAPREOMYCIN; CULTURE MEDIA; MICROBIAL SENSITIVITY TESTS; MYCOBACTERIUM TUBERCULOSIS;

EID: 26844566564     PISSN: 14760711     EISSN: 14760711     Source Type: Journal    
DOI: 10.1186/1476-0711-4-6     Document Type: Article

References (19)

1. Nuermberger E, Bishai WR, Grosset JH: Latent tuberculosis infection. Sem Resp Crit Care Med 2004, 25(3):317-336.
2. Wayne LG, Sohaskey CD: Nonreplicating persistence of Mycobacterium tuberculosis. Annu Rev Microbiol 2001, 55:139-193.
3. Dickinson JM, Mitchison DA: Experimental models to explain the high sterilizing activity of rifampin in the chemotherapy of tuberculosis. Am Rev Respir Dis 1981, 123:367-371.
4. Yuan Y, Crane DD, Barry CE: Stationary phase-associated protein expression of Mycobacterium tuberculosis: function of the mycobacterial alpha-chrystallin homolog. J Bacteriol 1996, 178:4484-4492.
5. Lyon RH, Lichstein HC, Hall WH: Factors affecting growth of Mycobacterium tuberculosis in aerobic and stationary cultures. Am Rev Respir Dis 1961, 83:255-260.
6. Wayne LG: Dynamics of submerged growth of Mycobacterium tuberculosis under anaerobic and microaerophilic conditions. Am Rev Respir Dis 1976, 114:807-811.
7. Heifets L, Lindholm-Levy P: Pyrazinamide sterilizing activity in vitro against semidormant Mycobacterium tuberculosis bacterial populations. Am Rev Respir Dis 1992, 145:1223-1225.
8. Wayne LG, Lin KY: Glyoxylate metabolism and adaptation of Mycobacterium truberculosis to survival under anaerobic conditions. Infect Immun 1982, 37:1042-1049.
9. Boon C, Li R, Qi R, Dick T: Proteins of Mycobacterium bovis BCG induced in the Wayne dormancy model. J Bacteriol 2001, 183:2672-2676.
10. Sherman DR, Voskuil M, Schnappinger D, Liao R, Harrel MI, Schoolnik GK: Regulation of the Mycobacterium tuberculosis hypoxic response gene encoding alpha-chrystallin. Proc Natl Acad Sci USA 2001, 98:7534-7539.
11. Voskuil MI, Schnappinger D, Visconti KC, et al.: Inhibition of respiration by nitric oxide induces a Mycobacterium tuberculosis dormancy program. J Exp Med 2003, 198:705-711.
12. Park HD, Guinn KM, Harrel MI, et al.: Rv3133c/dosR is a transcription factor that mediates the hypoxic response of Mycobacterium tuberculosis. Mol Microbiol 2003, 48:833-843.
13. Wayne LG, Sramek HA: Metronidazole is bactericidal to dormant cells of Mycobacterium tuberculosis. Antimicrob Agents Chemother 1994, 38:2054-2058.
14. Heifets L: MIC as a quantitative measurement of susceptibility of M. avium to seven antituberculosis drugs. Antimicrob Agents Chemother 1988, 32(8):1131-1136.
15. Heifets L, Lindholm-Levy PA: Comparison of bactericidal activities of streptomycin, amikacin, kanamycin, and capreomycin against M. avium and M. tuberculosis. Antimicrob Agents Chemother 1989, 33(8):1298-1303.
16. Mitchison DA: The action of antituberculosis drugs in shortcourse chemotherapy. Tubercle 1985, 66:219-225.
17. Bridle R, Odhiambo J, Mitchison D: Serial counts of Mycobacterium tuberculosis in sputum as surrogate markers of the sterilizing activity of rifampicin and pyrazinamide in treating pulmonary tuberculosis. BMC Pulm Med 2001, 1(1):2.
18. Jindani A, Dore CJ, Mitchison DA: Bactericidal and sterilizing activities of antituberculosis drugs during first 14 days. Am J Respir Crit Care Med 2003, 167(10):1299-1301.
19. Gosling RD, Heifets L, Gillespie SH: A multicentre comparison of novel surrogare marker for determining the specific potency of antituberculosis drugs. J Antimicrob Chemother 2003, 52(3):473-476.